All Articles

Arlo Technologies smashed expectations with record revenue, fueled by a masterful pivot to recurring services that now form the core of its business.

Twilio's stellar Q2 results boast record profits, but the real story lies in its AI-powered strategic shift, driving strong organic growth and future-proofing its platform.

Beyond the mixed GAAP results, ICU Medical’s strong non-GAAP growth and raised guidance reveal a company thriving after a strategic pivot.

iRhythm's stellar Q2 results are just the start. A major acquisition and a new AI algorithm are set to reshape the cardiac monitoring landscape.

After two years of losses, Silvaco is back in the black. A deep dive into the AI strategy and key partnerships with NVIDIA, Micron, and Dassault driving its comeback.

Octave Specialty Group's core insurance unit saw 77% revenue growth, fueled by strategic buys and a new AI underwriting platform that signals a tech-led future.

With its lead obesity drug in late-stage trials and a Novo Nordisk veteran newly hired, Structure Therapeutics is making a calculated play for the oral GLP-1 crown.

PAR Technology's Q2 results reveal soaring profitability and 19% revenue growth, prompting a raised 2026 outlook fueled by its AI-driven platform.

Ad tech firm PubMatic stuns Wall Street with a major Q2 comeback, as its AI platform and CTV focus drive an 11% revenue surge and expanded profits.

Apyx Medical's Q2 results show a 28% surge in its aesthetics unit, driven by the new AYON system. Is this strategic pivot away from OEM the key to its future?

With a $250M decision pending and a major acquisition closing, Zymeworks is betting its future on a radical pivot to a diversified, revenue-generating model.

Resmed posts record revenue and boosts shareholder returns, but its strategic pivot and operational hurdles reveal a more complex story of medtech leadership.

With 13% revenue growth and a massive buyback, CarGurus' Q2 results show its AI-first strategy is reshaping the auto market and rewarding investors.

Sprout Social's stellar Q2 profit beat isn't just a good quarter; it's a strategic overhaul. A look at its high-stakes bet on enterprise clients and AI.

With $911M in the bank, Relay Therapeutics is aggressively advancing its precision drug zovegalisib, targeting both breast cancer and rare vascular anomalies.

While Q2 results show a net loss, Bridger Aerospace secures record contracts and expands its tech, signaling a strategic shift for a new era of wildfire.

With late-stage trials underway and a cash runway into 2030, Trevi Therapeutics is accelerating its mission. But what does this mean for millions of unseen sufferers?

The nation's only public parking firm faces an insider offer, placing a special committee at the center of a high-stakes test for shareholder value.

The software supply chain firm's Q2 results beat estimates, with cloud revenue soaring 53% as its security platform becomes essential for the AI era.

A new press release touts 'simplicity' as the future of digital entertainment. But for online gaming platform Mr Win77, are the real complexities hidden?